Bright Minds Biosciences (DRUG) Payables (2020 - 2026)

Bright Minds Biosciences' Payables history runs 7 years deep, the most recent figure standing at $2.7 million for Q1 2026.

• Quarterly Payables rose 600.5% year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 million (up 600.5% YoY) and the FY2025 annual result came in at $1.6 million, up 447.45% from the prior year.
• Payables was $2.7 million for Q1 2026 at Bright Minds Biosciences, up from $1.1 million in the prior quarter.
• Across five years, Payables topped out at $2.7 million in Q1 2026 and bottomed at $120354.5 in Q2 2024.
• A 5-year average of $701854.8 and a median of $478983.7 in 2023 frame the typical range for Payables.
• Annual changes were most pronounced in 2022 — Payables jumped 133240.8% — and 2023, when it sank 85.64%.
• Bright Minds Biosciences' Payables stood at $337544.0 in 2022, then jumped by 74.0% to $587332.4 in 2023, then plunged by 52.61% to $278362.9 in 2024, then surged by 284.97% to $1.1 million in 2025, then jumped by 155.22% to $2.7 million in 2026.
• Business Quant data shows DRUG's Payables at $2.7 million in Q1 2026, $1.1 million in Q4 2025, and $1.6 million in Q3 2025.